Activated protein C

ApprovedSmall molecule

UUniversity of Roma La Sapienza

Activated protein C is one of 92 small molecule programs targeting Acute Pancreatitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute PancreatitisActive, not recruiting

StrokeActive, not recruiting

Septic ShockActive, not recruiting

Acute PancreatitisApproved

Active, not recruiting

StrokePhase 2

Active, not recruiting

Septic ShockPhase 2

Active, not recruiting

Competition

Competitive Landscape

461 competitors in Stroke

#DrugCompanyPhaseTrials

Activated protein C

UUniversity of Roma La Sapienza

Approved

1 2

Folvite

Eli Lilly

Preclinical

1 3

Savella

AbbVie

Preclinical

1 4

Proamatine

Repatha

Botox

RRevance Therapeutics, Inc.

Preclinical

2 7

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Alka-Seltzer

AAbbott

Preclinical

1 9

Direct Anticoagulant

Bayer

Preclinical

3 10

Carbidopa-Levodopa

Neurocrine Biosciences

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Septic Shock1 trial

Administration of Human Protein C Concentrates in Patients With Sepsis and Septic Shock.

Completed·UUniversity of Roma La Sapienza·Phase 2·NCT01411670·60 enrolled

Acute Pancreatitis1 trial

Activated Protein C in Severe Acute Pancreatitis

Completed·HHelsinki University Central Hospital·Phase 4·NCT01017107·32 enrolled

Stroke1 trial

Activated Protein C in Acute Stroke Trial

Terminated·UUniversity of Rochester·Phase 2·NCT00533546·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Activated protein C. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Activated protein C compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Activated protein C. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Roma La Sapienza company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Roma La Sapienza

Activated protein C

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Septic Shock1 trial

Acute Pancreatitis1 trial

Stroke1 trial

References

Drug Info

Quick Facts

Related News